A2AR-antagonist-1 is an orally active adenosine A2A receptor (A2AR) antagonist with antitumor activity; it enhances T cell activation by inhibiting immune checkpoint molecules (LAG-3 and TIM-3) and upregulating effector molecules (GZMB, IFNG, and IL-2).